glp-1 agonists with cardiovascular benefit receptor agonists: The benefits beyond glucose control In patients with #obesity, incretin-based

The consistency across doses suggests this is not simply a downstream effect of weight loss but may represent a direct pharmacological action on inflammatory pathways

Combination therapies (GLP-1s with other peptides, metabolic drugs, or lifestyle protocols like the ProLon Fasting Mimicking Diet ) are already being studied to push results even further

However, our results do not necessarily suggest that everyone with type 2 diabetes should receive an SGLT2i, nor do they address other considerations about widespread SGLT2i use

This isn't Pfizer's first GLP-1 play through China either

Herron E, Cencetti J, Matis J

As GLP-1s continue to develop, including enhanced mechanisms of action such as dual or triple agonism, they could have even greater neuroprotective effects, Thiara wrote